Brief: SCYNEXIS Announces Achievement Of First Development Milestone Of $25 Mln Under Exclusive License Agreement With GSK
21/06/2023 12:07
June 21 (Reuters) - SCYNEXIS Inc SCYX.O :
* SCYNEXIS ANNOUNCES ACHIEVEMENT OF FIRST DEVELOPMENT
MILESTONE OF
$25 MILLION UNDER EXCLUSIVE LICENSE AGREEMENT WITH GSK
* SCYNEXIS INC - ACHIEVEMENT OF $25 MILLION
PERFORMANCE-BASED
DEVELOPMENT MILESTONE UNDER ITS EXCLUSIVE LICENSE AGREEMENT WITH
GSK FOR IBREXAFUNGERP
Source text for Eikon: ID:nGNX1wvTwW
Further company coverage: SCYX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Scynexis
See all newsBrief: Scynexis Announces Phase 1 Study Results For Scy-770, A Novel, Highly Selective, Oral Direct Ampk Activator For The Treatment Of Autosomal Dominant Polycystic Kidney Disease
Brief: Scynexis Announces Appointment Of Sanjay Subramanian As Chief Financial Officer
Scynexis Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Scynexis Q2 swings to profit on warrant adjustment; advances drug studies
Scynexis Inc Expected To Post A Loss Of 51 Cents A Share: Earnings Preview